SCHEMBL29270742

SCHEMBL29270742

CC(C)(C[C@H]1CSc2ccc(C(=O)NN)cc2NC1=O)NC(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.41
▸ HDAC8 Q9BY41 2/20 0.41
▸ HDAC6 Q9UBN7 2/20 0.41
▸ POLB P06746 3/20 0.40
▸ HPGD P15428 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ RAB9A P51151 5/20 0.38
▸ NPC1 O15118 4/20 0.38
▸ HTT P42858 2/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ LMNA P02545 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ MAPT P10636 2/20 0.36
▸ ATM Q13315 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ PABPC1 P11940 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29270794 0.89 HDAC1 (0.39) HDAC1HDAC8HDAC6POLBHPGD
SCHEMBL29270724 0.83 SSTR4 (0.36) HDAC1HDAC8HDAC6POLBSMN1; SMN2
SCHEMBL29270801 0.81 LMNA (0.35) HDAC1HDAC8HDAC6POLBSMN1; SMN2
SCHEMBL26962754 0.78 HDAC1 (0.44) HDAC1HDAC8HDAC6POLBHPGD
SCHEMBL29270708 0.78 TP53 (0.34) HDAC1HDAC8HDAC6POLBSMN1; SMN2
SCHEMBL29270757 0.76 CYP2C9 (0.33) —
SCHEMBL29270754 0.75 AKR1B1 (0.32) LMNA
SCHEMBL26962078 0.74 HPGD (0.41) HDAC1HDAC8HDAC6POLBHPGD
SCHEMBL29796987 0.74 HPGD (0.41) HDAC1HDAC8HDAC6POLBHPGD
SCHEMBL29270847 0.74 TP53 (0.47) SMN1; SMN2NPC1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116964048-A Bicyclic tetrahydroazepine derivatives for the treatment of cancer 豪夫迈·罗氏有限公司 2023-10-27 — — CN disclosed
Send feedback